Antimalarial drug discovery: Progress and approaches

JL Siqueira-Neto, KJ Wicht, K Chibale… - Nature Reviews Drug …, 2023 - nature.com
Recent antimalarial drug discovery has been a race to produce new medicines that
overcome emerging drug resistance, whilst considering safety and improving dosing …

Antimalarial drug resistance in Africa: the calm before the storm?

MD Conrad, PJ Rosenthal - The Lancet Infectious Diseases, 2019 - thelancet.com
Antimalarial drug resistance, in particular resistance to Plasmodium falciparum, challenges
the treatment and control of malaria. In this Review, we summarise evolving patterns of …

[HTML][HTML] Plasmodium vivax in the era of the shrinking P. falciparum map

RN Price, RJ Commons, KE Battle, K Thriemer… - Trends in …, 2020 - cell.com
Plasmodium vivax is an important cause of malaria, associated with a significant public
health burden. Whilst enhanced malaria-control activities have successfully reduced the …

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria

A Llanos-Cuentas, MVG Lacerda, TT Hien… - … England Journal of …, 2019 - Mass Medical Soc
Background Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been
associated with relapse prevention through the clearance of P. vivax parasitemia and …

Update on malaria

R Varo, C Chaccour, Q Bassat - Medicina Clínica (English Edition), 2020 - Elsevier
Despite recent successful efforts to reduce the global malaria burden, this disease remains a
significant global health problem. Only in 2018, malaria caused 228 million clinical …

Diagnosis, treatment, and prevention of malaria in the US: a review

JP Daily, A Minuti, N Khan - Jama, 2022 - jamanetwork.com
Importance Malaria is caused by protozoa parasites of the genusPlasmodiumand is
diagnosed in approximately 2000 people in the US each year who have returned from …

[HTML][HTML] Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial

WRJ Taylor, K Thriemer, L von Seidlein, P Yuentrakul… - The Lancet, 2019 - thelancet.com
Background Primaquine is the only widely used drug that prevents Plasmodium vivax
malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …

[HTML][HTML] Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis

RJ Commons, JA Simpson, J Watson… - The American journal …, 2020 - ncbi.nlm.nih.gov
Plasmodium vivax and Plasmodium ovale form dormant liver hypnozoites that can reactivate
weeks to months following initial infection. Malaria recurrences caused by relapses are an …

[HTML][HTML] Resolving the cause of recurrent Plasmodium vivax malaria probabilistically

AR Taylor, JA Watson, CS Chu, K Puaprasert… - Nature …, 2019 - nature.com
Relapses arising from dormant liver-stage Plasmodium vivax parasites (hypnozoites) are a
major cause of vivax malaria. However, in endemic areas, a recurrent blood-stage infection …

The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis

JA Watson, RJ Commons, J Tarning, JA Simpson… - Elife, 2022 - elifesciences.org
Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax
malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual …